Policy | March 22, 2022
Mandaviya launches BRICS vaccine R&D centre
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
DASH enables non-laboratory personnel to insert a nasal swab specimen directly into our test cartridge and then load the cartridge into the DASH instrument, providing an accurate result in about 15 minutes
Empowers the lab to do more in less time within the existing floor plan by integrating clinical chemistry and immunoassay testing onto a single platform
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Subscribe To Our Newsletter & Stay Updated
